A Study of the Efficacy and Safety of MK-5475 in ...
2021-2-1 · Placebo administered as dry powder inhalation Experimental: Phase 3 Cohort MK-5475 Participants receive one of 3 MK-5475 doses (380, 100 or 32 µg) to be selected at end of the Phase 2 Cohort, administered via oral inhalation once daily for 12-week base period and up to …
Get Price